What The Study Did:
In this phase 1 study, a single immunization with Ad26.COV2.S (Janssen/Johnson & Johnson) vaccine induced rapid binding and neutralization antibody responses as well as cellular immune responses. Two phase 3 clinical trials are currently underway to determine the efficacy of the Ad26.COV2.S vaccine.
Authors:
Dan H. Barouch, M.D., Ph.D., of Beth Israel Deaconess Medical Center in Boston, is the corresponding author.
To access the embargoed study:
Visit our For The Media website at this link
https:/
/
media.
jamanetwork.
com/
(doi:10.1001/jama.2021.3645)
Editor’s Note:
Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
###
Media advisory:
The full article is linked to this news release.
Embed this link to provide your readers free access to the full-text article
This link will be live at the embargo time
https:/
/
jamanetwork.
com/
journals/
jama/
fullarticle/
10.
1001/
jama.
2021.
3645?guestAccessKey=
1d3b0702-ad7c-4150-85fc-c526b5290ac0&utm_source=
For_The_Media&utm_medium=
referral&utm_campaign=
ftm_links&utm_content=
tfl&utm_term=
031121
This part of information is sourced from https://www.eurekalert.org/pub_releases/2021-03/jn-ioa031121.php